The protective potency of two commonly used cardioplegic solutions on cultured endothelial cells exposed to free-oxygen radicals injury.
Human umbilical vein endothelial cells were incubated with Bretschneider and St. Thomas II cardioplegic solution followed by a stimulation with cumene hydroperoxide (CHPO), which was used as an oxygen radicals generating agent. A statistically significant decrease of intracellular high energy phosphates (adenosine-5-trisphosphate: ATP; creatine phosphate: CP) compared to controls was observed in response to Bretschneider cardioplegia and CHPO. Furthermore, significant rises in prostaglandin I2 (prostacyclin; PGI2) production and lipidperoxidation were measured. The authors failed to record such alterations of endothelial cell metabolism for the St. Thomas II cardioplegic solution. They could also demonstrate that the cellular protection against oxygen radicals exerted by the St. Thomas II solution is attributable to procaine. The enhanced cytotoxicity of CHPO observed in presence of the Bretschneider solution was found to be partially caused by its constituent L-histidine, which led to significant decreases of high energy phosphates and increased lipidperoxidation when cells were subsequently treated with CHPO. However, alterations of high energy phosphate content initiated by CHPO and amplified by the Bretschneider solution could not be inhibited by adding procaine. Simultaneous pretreatment of cells with the Bretschneider solution and procaine and stimulation with CHPO resulted in decreases of ATP and CP, as observed using the Bretschneider cardioplegia alone.
Weigel
G
G
2nd Department of Surgery, University of Vienna, Austria.
Griesmacher
A
A
Toma
C
C
Leukauf
C
C
Schreiner
W
W
Wolner
E
E
D000255:Adenosine Triphosphate / Q000032:analysis; D001555:Benzene Derivatives; D002314:Cardioplegic Solutions / Q000737:chemistry / Q000494:pharmacology*; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects*; D011464:Epoprostenol / Q000032:analysis; D006639:Histidine / Q000494:pharmacology*; D006801:Humans; D018384:Oxidative Stress; D010725:Phosphocreatine / Q000032:analysis; D011343:Procaine / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000032:analysis*; D013696:Temperature; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D014471:Umbilical Veins
D001555:Benzene Derivatives; D002314:Cardioplegic Solutions; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D010725:Phosphocreatine; D006639:Histidine; D011343:Procaine; D000255:Adenosine Triphosphate; D011464:Epoprostenol; C007164:cumene hydroperoxide